ethyl 3,3-bis(3-fluorophenyl)acrylate | 170019-22-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3,3-bis(3-fluorophenyl)acrylate
• 英文别名: ethyl 3,3-bis(3-fluorophenyl)prop-2-enoate
• CAS: 170019-22-4
• 化学式: C₁₇H₁₄F₂O₂
• 分子量: 288.294
• InChiKey: JWNTYVVENZPPMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3,3-bis(3-fluorophenyl)acrylate 在 氢氧化钯 氢气 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以to afford 39.08 g (100%) of the title compound as a clear, colorless oil的产率得到Ethyl 3,3-bis(3-fluorophenyl)propionate
  参考文献：
  名称：

  Anticonvulsant and central nervous system-depressing bis(fluorophenyl)alkylamides and their uses

  摘要：

  已经合成了具有有益药理特性（例如，抗惊厥活性）的双（氟苯基）烷基酰胺，可用于治疗神经系统疾病或障碍，例如癫痫、惊厥和癫痫性障碍。本发明的优选化合物还几乎不引起镇静，并在癫痫动物模型中具有高治疗和保护指数。这些化合物还具有长的药理半衰期，这在实际的临床治疗应用中应该转化为每天一次的用药，对患有这些疾病和/或障碍的患者非常有益。这些化合物还可能在中枢和外周神经系统的其他疾病和障碍的治疗中具有进一步的临床用途，或者受其影响的疾病或障碍，包括但不限于痉挛、骨骼肌痉挛和疼痛、不安和压力以及双相情感障碍。

  公开号：

  US06617358B1
• 作为产物：
  描述：

  间溴氟苯 、 丙烯酸乙酯 在 dipalladium(II)(1,1'-di-t-butyl-3,3'-(1,2-ethanediyl)bisimidazolium)dipyridinetetradichloride 、 四丁基溴化铵 、 sodium acetate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 18.0h， 以82%的产率得到ethyl 3,3-bis(3-fluorophenyl)acrylate
  参考文献：
  名称：

  二碳烯二钯配合物催化的可控单-和双-Heck反应

  摘要：

  描述了末端烯烃与缺电子和富电子的芳基卤化物（碘化物和溴化物）的无膦单-和双-Heck反应。通过控制芳基卤化物和烯烃的化学计量，钯催化剂的负载，以及使用不同的碱，有或没有添加剂，二碳二烯二钯配合物1催化这些反应。双-Heck反应的方法允许末端烯烃的β，β-二芳基化和β，β′-二芳基化，并以良好或优异的产率提供三取代的烯烃。

  DOI：

  10.1016/j.tet.2013.05.030

文献信息

• Palladium-catalyzed double arylations of terminal olefins in acetic acid
  作者：Daichao Xu、Chunxin Lu、Wanzhi Chen

  DOI：10.1016/j.tet.2011.12.017

  日期：2012.2

  A palladium-catalyzed Heck diarylation of terminal olefins under ligand-free conditions in acetic acid is described. This procedure allows double arylation of terminal olefins affording trisubstituted olefins in good to excellent yields. The methodology is applicable to the coupling of both electron-deficient and electron-rich aryl iodides leading to symmetrical and unsymmetrical β,β-diarylated alkenes

  描述了在无配体条件下在乙酸中钯催化的末端烯烃的Heck二芳基化。该方法允许末端烯烃进行双芳基化，从而以良好至优异的产率提供三取代的烯烃。该方法适用于缺电子和富电子的芳基碘化物的偶合，从而导致对称和不对称的β，β-二芳基化烯烃。
• Compounds active at a novel site on receptor-operated calcium channels
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US06017965A1

  公开（公告）日：2000-01-25

  Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

  治疗患有神经系统疾病或障碍的患者的方法和组合物，例如中风，头部创伤，脊髓损伤，脊髓缺血，缺血或低氧引起的神经细胞损伤，癫痫，焦虑，由于缺血或低氧引起的神经心理或认知缺陷，例如常见于心脏手术下心肺旁路的后果，或神经退行性疾病，例如阿尔茨海默病，亨廷顿病，帕金森病或肌萎缩性侧索硬化症（ALS）。
• Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US20020004522A1

  公开（公告）日：2002-01-10

  Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

  本发明涉及一种用于治疗患有神经系统疾病或障碍的患者的方法和组合物，例如中风、头部创伤、脊髓损伤、脊髓缺血、缺血或缺氧引起的神经细胞损伤、癫痫、焦虑、神经精神或认知缺陷，由于缺血或缺氧而经常发生在心脏手术下心肺转流的后果，或神经退行性疾病，例如阿尔茨海默病、亨廷顿病、帕金森病或肌萎缩侧索硬化症（ALS）。
• Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their uses
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US20030199589A1

  公开（公告）日：2003-10-23

  Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological diseases or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacologic half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

  已经合成了具有有益药理特性（例如，抗惊厥活性）的双（氟苯基）烷基酰胺类化合物，可用于治疗神经系统疾病或障碍，例如癫痫、抽搐和癫痫性疾病。本发明的优选化合物还会引起较少的镇静作用，并在癫痫动物模型中具有高的治疗和保护指数。这些化合物还具有长的药理学半衰期，在实际的临床治疗应用中，应该可以转化为一天一次的剂量，对于患有这些疾病和/或障碍的患者非常有益。这些化合物还可能在治疗中枢和外周神经系统的其他疾病和障碍，或受其影响的疾病和障碍方面具有进一步的临床实用性，包括但不限于痉挛、骨骼肌痉挛和疼痛、不宁腿综合症、焦虑和压力以及双相障碍。
• Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1640359A2

  公开（公告）日：2006-03-29

  Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological disease or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacologic half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

  双(氟苯基)烷基酰胺已被化学合成，具有有益的药理特性（如抗惊厥活性），可用于治疗神经系统疾病或紊乱，如癫痫、抽搐和癫痫发作紊乱等。本发明的优选化合物也几乎不会引起镇静，在癫痫动物模型中具有较高的治疗和保护指数。这些化合物还具有较长的药理半衰期，在实际临床治疗应用中，可实现一天一次给药，对这些疾病和/或失调患者大有裨益。这些化合物在治疗中枢和周围神经系统的其他疾病和失调，或受其影响的疾病或失调，包括但不限于痉挛、骨骼肌痉挛和疼痛、不安腿综合征、焦虑和压力，以及躁郁症等方面，也可能具有进一步的临床效用。